Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading Volume – Should You Buy?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) saw an uptick in trading volume on Monday . 248,495 shares traded hands during mid-day trading, a decline of 13% from the previous session’s volume of 284,261 shares.The stock last traded at $21.1950 and had previously closed at $20.75.

Analyst Ratings Changes

A number of research analysts recently issued reports on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Pulse Biosciences presently has a consensus rating of “Hold” and a consensus price target of $26.00.

Pulse Biosciences Price Performance

The stock has a market capitalization of $1.64 billion, a P/E ratio of -21.42 and a beta of 1.77. The company’s 50-day simple moving average is $14.29 and its 200-day simple moving average is $15.46.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of PLSE. BNP Paribas Financial Markets raised its stake in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after acquiring an additional 1,300 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after acquiring an additional 1,372 shares during the period. Westside Investment Management Inc. lifted its holdings in Pulse Biosciences by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the period. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.